Medical Oncology, Harvard Medical School, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA.
Medical Oncology, Harvard Medical School, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA.
Surg Oncol Clin N Am. 2020 Jan;29(1):115-125. doi: 10.1016/j.soc.2019.08.009.
Diffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin lymphoma, is characterized by both clinical and molecular heterogeneity. Despite efforts to tailor therapy for individual patients, treatment remains uniform and a subset of patients have poor outcomes. The past decade has witnessed a dramatic expansion of our understanding of the genomic underpinnings of this disease, especially with the application of next-generation sequencing. In this review, the authors highlight the current genomic landscape of DLBCL and how this information provides a potential molecular framework for precision medicine-based strategies in this disease.
弥漫性大 B 细胞淋巴瘤（DLBCL）是最常见的非霍奇金淋巴瘤亚型，具有临床和分子异质性。尽管为个体患者量身定制治疗的努力一直在进行，但治疗仍然是统一的，一部分患者的预后较差。在过去的十年中，我们对这种疾病的基因组基础有了更深入的了解，特别是在下一代测序的应用方面。在这篇综述中，作者强调了 DLBCL 的当前基因组景观，以及这些信息如何为该疾病的精准医学策略提供潜在的分子框架。
